Cosmos Health Inc. Reports Strong First-Quarter 2025 Performance

Stockholders' equity increased by $1.42 million, while the liabilities-to-assets ratio remained a modest 54.6%, reflecting continued financial discipline.

Cosmos Health, Inc. (Nasdaq: COSM) today announced its financial results for the first quarter of 2025.

For the quarter, the company reported a net loss of $0.19 million, or $0.01 loss per share, on adjusted net income. This compares to adjusted net income of $3.41 million, or $0.18 earnings per share, in the prior-year period. The company also reported adjusted EBITDA of $0.1 million, compared to adjusted EBITDA of $3.3 million in the prior-year quarter.

"We are pleased with our strong first-quarter performance and the steady progress across multiple strategic areas," said Greg Siokas, CEO of Cosmos Health. "Gross profit and gross margins increased significantly, supported by an improved product mix and stronger operating leverage. Our continued focus on efficiency and disciplined cost management is yielding tangible results, as reflected in our return to profitability on both an Adjusted EBITDA and Adjusted Net Income basis."

The company's stock price increased by 5.3% to $57.2 million as of March 31, 2025, from $54.3 million as of December 31, 2024. The increase in stockholders' equity was due to several factors, including the company's focus on reducing liabilities-to-assets ratio, which remained a modest 54.6%.

"Despite the challenging macroeconomic environment, we continue to execute on our key priorities and deliver solid financial performance," said Siokas. "We are confident in our ability to drive further growth and value creation for our shareholders in the quarters to come."

The company also announced that it has entered into an agreement to provide a portion of its preferred stock to a strategic investor in exchange for a minimum investment of $20 million in Cosmos’ common stock over a period of 12 months following the closing of the preferred stock purchase agreement. The strategic investor will also become a member of Cosmos' Board of Directors.

"This partnership marks a significant milestone for Cosmos as we navigate the final stage of our journey to profitability and expand our footprint in the global health and wellness market," said Siokas. "We are grateful for the trust and confidence shown by this investor, and we believe this collaboration will be instrumental in driving Cosmos's long-term success."

Cosmos Health is a diversified, vertically integrated global health group, founded in 1990 and based in Greece with a subsidiary in the U.S., operating in accordance with European and U.S. regulations. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in accordance with European GMP, and distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.

Cosmos’ products are sold in a wide range of channels, including food retailers, convenience stores, pharmacies, e-commerce platforms and social media channels. The company's products are available in several major markets worldwide, including Greece, Cyprus, Israel, Bulgaria, Romania, Turkey, Egypt, the U.K., Germany, France, Spain, Italy, Benelux, Scandinavia, the Baltic States, the Middle East, and North America, through partnerships with local distributors.

The company is expanding its product portfolio with a focus on R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and developing novel patented nutraceuticals, specialized root extracts, proprietary complex generics and innovative OTC products.

Cosmos is also entering the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, U.S., and is integrating this technology to provide patients with seamless access to medical care.

The company is expanding throughout Europe, Asia and North America, with offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, U.K.

Cosmos Health is publicly traded on Nasdaq under the symbol COSM. The company is included in the Nasdaq Small Cap Index and the Global Health Technology Index.